A Randomized, Controlled Trial of Daclizumab vs Anti-thymocyte Globulin Induction for Lung Transplantation

DZM is a safe component of induction therapy in lung transplantation. In addition, DZM may prolong freedom from acute rejection. Significant infections were more frequent in the DZM group, but this was likely due to a higher incidence of CMV mismatch. Both methods of induction therapy worked well, with excellent 1-year survival.